This study highlights that in patients with BRAFv600 MM treated with BRAF‐i/MEK‐i, the presence of DDI‐H emerges as a negative prognostic factor; in particular, DDI appears to be significantly associated with worse oncological outcomes in terms of OS and PFS regardless of clinical risk. Here, BRAF is linked to Miyoshi myopathy.